Detalles de la búsqueda
1.
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Sci Transl Med
; 8(334): 334ra53, 2016 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27075627
2.
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Clin Cancer Res
; 22(6): 1499-509, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26515496
3.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Cancer Discov
; 4(2): 232-45, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356096
4.
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Clin Cancer Res
; 25(4): 1437, 2019 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30770496
5.
Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Breast
; 20(1): 39-45, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20705464
6.
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Clin Cancer Res
; 16(21): 5351-61, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20829329
Resultados
1 -
6
de 6
1
Próxima >
>>